A PHASE 1, RANDOMIZED, OPEN LABEL, 2 WAY CROSSOVER STUDY TO DEMONSTRATE A LACK OF AN EFFECT OF MULTIPLE DOSE PF 06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS
Latest Information Update: 19 Nov 2019
At a glance
- Drugs Ritlecitinib (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 13 Nov 2019 Status changed from recruiting to completed.
- 05 Sep 2019 Planned End Date changed from 1 Oct 2019 to 15 Oct 2019.
- 05 Sep 2019 Planned primary completion date changed from 1 Oct 2019 to 15 Oct 2019.